None listed
Conditions
Brief summary
Twenty four COPD patients in stable clinical conditions, for at least one month, are going to be enrolled in the study. The tests are going to be performed in two ocasions, at least two days apart. All the patients will go to the pulmonary function laboratory without use of any bronchodilator for at least 12 hours. They are going to perform a simple spirometry at baseline and minutes after an inhalation with 300 mg of magnesium or placebo. After a second spirometry, the patients are going to receive an additional inhalation with salbutamol 2.5 mg. The patients are going to perform a third spirometry minutes after the last inhalation. Finally they are going to perform a six minute walk test in both ocasions.
Interventions
All patients are going to be evaluated in two occasions within a crossover design
First treatment day:
#Inhalation of 300 mg of magnesium sulphate for 10 minutes.
# A 10 minute rest period
# Spirometry test
# Inhalation of 2,5 mg of salbutamol for 10 minutes after the spirometry.
# A second spirometry 10 minutes after the end of the inhalation of salbutamol
# A six minute walk test 10 minutes after the end of the last inhalation.
All treatments are going to be administered only one time. A 48 h
All patients are going to be evaluated in two occasions within a crossover design First treatment day: #Inhalation of 300 mg of magnesium sulphate for 10 minutes. # A 10 minute rest period # Spirometry test # Inhalation of 2,5 mg of salbutamol for 10 minutes after the spirometry. # A second spirometry 10 minutes after the end of the inhalation of salbutamol # A six minute walk test 10 minutes after the end of the last inhalation. All treatments are going to be administered only one time. A 48 hours wash-out period is going to respected between the first and second treatment days.
Sponsors
José Antônio Baddini Martinez MD, PhD
Study design
Allocation
Randomised controlled trial
Intervention model
Crossover
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
Patients with chronic obstructive pulmonary disase of any severity.
Exclusion criteria
Active smokers; patients with any cardiac condition, diabetes mellitus or kidney failure.
Outcome results
None listed